Skip to main content

Meisner Lara's Form 4 filing

Viridian Therapeutics, Inc. (VRDN) · filed Jun 20, 2023

Accession no.
0000899243-23-015998
Filed
Jun 20, 2023
Trade date
Jun 15-16, 2023
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $64.3K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Meisner LaraCIK 0001883986Officer (Chief Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 15, 2023Common StockMOption exerciseAcquired+2,269$23.03+$52,255.0732,240Direct
Jun 15, 2023Common StockSSaleDisposed−2,269$28.02−$63,577.3829,971Direct
Jun 16, 2023Common StockMOption exerciseAcquired+27$23.03+$621.8129,998Direct
Jun 16, 2023Common StockSSaleDisposed−27$28.35−$765.4529,971Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 15, 2023Common StockMOption exerciseDisposed−2,269$0.00$037,481Direct
Jun 16, 2023Common StockMOption exerciseDisposed−28$0.00$037,453Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)